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On 18 January 2012, the Americas Hepato-Pancreato-Biliary
Association (AHPBA) convened a Consensus Conference on the
multidisciplinary treatment of colorectal cancer liver metastases
(CRLM). The event followed the format of previous consensus
conferences, and as in previous years was cosponsored by the
Society of Surgical Oncology, the Society for Surgery of the Ali-
mentary Tract and the University of Texas MD Anderson Cancer
Center. The goals of this conference included the assembly of
international experts on the diagnosis and treatment of CRLM,
presentations and discussions on evolving standards for themulti-
disciplinary approach to CRLM, and initiation and facilitation of
a consensus-finding process regarding novel aspects within the
field. The meeting took place over 1 day and consisted of three
sessions that focused on the topics of selection for hepatic resec-
tion, locoregional surgical and interventional therapies, and sys-
temic cytotoxic and biological therapies.
This issue of HPB contains three manuscripts, each represent-
ing the content of one session, including summaries of subtopics
as well as a listing of the resulting consensus statements.1–3 The
process and organization of this event was kept quite similar to
earlier consensus conferences on hepatic colorectal cancer metas-
tases,4 resectable and borderline resectable pancreatic cancer5 and
hepatocellular cancer.6 After preparatory steps among experts
within the specialty and in consultation with the co-sponsoring
societies, a programme with relevant innovative topics on CRLM
was compiled, and a group of thought leaders was identified and
invited to serve a presenters or panelists during the conference.
Each presenter was requested to summarize relevant data on a
specific subtopic, and to propose statements that could serve as a
basis for a subsequent consensus. A panel of experts was invited to
comment on the presentation topic and the proposed statements,
and the conference audience was encouraged to participate in this
discussion. After the symposium, three manuscripts were written
by the presenters and these have been reviewed by the session
panelists whose accompanying commentaries are also included
in this issue.
A previous consensus conference held in 2006 had addressed
the topic of CRLM, and provided statements regarding the selec-
tion of patients for resection, methods of improving resectabil-
ity, and the selection of systemic chemotherapy and regional
treatments.4 Why, then, should there be another consensus con-
ference on CRLM after an interval of just 6 years? What may
seem to be an event at risk of premature repetition is actually a
reflection of the significant and rapid advances that have been
made in the multidisciplinary approach to CRLM during this
short time span.
Improved accuracy of pre-operative imaging has guided local
and regional therapies to greater anatomic precision and better
patient selection. High-quality imaging at baseline appears to be
crucial for developing a successful multidisciplinary plan. We
have learned that traditional means of radiographical response
assessment to induction therapy carry limitations, and that novel
response parameters are better predictors of systemic therapy
efficacy and tumour biology. Questions on what can be resected
and what should be resected have been better defined, especially
in the light of effective systemic therapy leading to disappearing
metastases. The experience with extensive non-anatomic resec-
tions or staged approaches for bilateral CRLM has grown signifi-
cantly, as has the spectrum of options in the approach to patients
with primary colon or rectal cancers and synchronous CRLM. An
entire spectrum of therapeutic options for local ablative and
regional therapies has emerged, and requires a balanced
approach that provides the individual patient with those options
that can ascertain a best possible result. Finally, systemic treat-
ment options are rapidly expanding with cytotoxic and/or bio-
logical therapeutics providing significant gains, both for an
adjuvant indication as well as for definitive therapy of ultimately
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unresectable disease. Importantly, the increased use of chemo-
therapy as a pre-operative treatment has led to advances in the
understanding of chemotherapy-associated liver injury mecha-
nisms, thereby setting new standards for type and duration of
such approaches.
A ‘consensus’ in this arena of interactions between multiple
specialties cannot be expected to be truly complete or to remain
permanent. The interested reader will undoubtedly recognize
that the current statements only represent a contemporary snap-
shot of specific aspects within a rapidly developing field, and
that they are intended to complement evolving evidence-based
practice standards. Their desired purpose is primarily to enhance
the multidisciplinary awareness, commitment and directives of
physicians involved in the care of CRLM patients. We are
encouraged by the developments within the field, and hope that
the inclusion of these novel contributions to the consensus
guidelines contributes to the process of achieving a balanced
multidisciplinary therapy strategy for every patient with CRLM
and thus of enhancing the quality of care. We thank those who
actively contributed to the consensus-finding effort to create
such a possibility.
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